In the throes of an opioid epidemic, the US Food and Drug Administration (FDA) decided in August 2015 to expand the indications for OxyContin, an extended-release form of the narcotic oxycodone, to children aged 11 years and older. The decision sparked outrage in those who fear the move might fuel increasing opioid addiction among young Americans.
Researchers examining Medicare prescribing patterns of oral anticoagulants and non-insulin diabetes drugs have found that pharmaceutical marketing to physicians involving payments was associated with physicians being more likely to prescribe those marketed drugs.
The costs of popular drugs—even generics—in dermatology are soaring, leaving patients scrambling for coverage or financial assistance and dermatologists spending precious hours on prior authorizations, drug appeals and reviews. In this first of a five-part series, experts and patients help define the problem.
ISDIN, a Barcelona-based dermatological solutions company, launched a handful of products in the U.S. in July and plans to expand its presence, as well as add a line of cosmeceuticals, before the close of 2016.
Syphilis has made a resurgence in the U.S., with the number of new cases increasing annually for the last 15 years. New screening recommendations identify patient populations that require at least annual screenings. An expert shares what all this means for dermatologists.